logo-loader

BioVie reports positive Phase 2 Parkinson’s data for bezisterim

Published: 00:53 21 Oct 2026 AEDT

Screenshot-2022-10-27-at-10-34-58-AM

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson’s drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological Association’s annual meeting in San Diego. 

The randomized, double-blind, placebo-controlled trial enrolled 57 patients, who received bezisterim or placebo for 12 weeks. Researchers tracked motor and non-motor symptoms, daily functioning, sleep, inflammatory biomarkers and overall benefit, using a Composite Benefit Score (CBS). 

BioVie’s Parkinson’s drug bezisterim improved symptoms in early-stage patients with higher inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological Association meeting. In this subgroup, about half of the 57-patient trial, treated patients improved on motor and non-motor scores while placebo patients worsened slightly.  

Across all patients, 25% on bezisterim saw meaningful improvement versus 4% on placebo, and the risk of meaningful worsening was about 70% lower (14% versus 46%). Adverse events were less common with the drug (39.3% versus 51.7%), with no severe or serious events in either group. 

Treatment-emergent adverse events occurred in 39.3% of bezisterim patients and 51.7% of placebo patients. No severe or serious adverse events were reported in either group, and each arm had one potentially treatment-related event. 

BioVie’s Clarence Ahlem said the results show an anti-inflammatory treatment can benefit both motor and non-motor symptoms, and that the findings support further development of bezisterim, including its potential to affect the underlying disease process. 

The abstract was published in Annals of Neurology. 

XanaMIA results: What's next for Actinogen Medical?

Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study revealed encouraging signs of disease slowing in patients aged...

10 hours, 18 minutes ago